Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

139.55 +1.09 (+0.79%)
Streaming Delayed Price Updated: 11:18 AM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,851
Open 139.40
Bid (Size) 139.47 (1)
Ask (Size) 139.59 (2)
Prev. Close 138.46
Today's Range 138.59 - 140.13
52wk Range 125.36 - 169.98
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
The cannabis sector has been disappointing in recent years, but this company stands out. 
Via The Motley Fool
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain
Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.  
Via Benzinga

Performance

YTD
-10.75%
-10.75%
1 Month
-3.77%
-3.77%
3 Month
-11.93%
-11.93%
6 Month
+4.70%
+4.70%
1 Year
-12.50%
-12.50%

More News

Read More
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Via Benzinga
Zymeworks Offers Hope for More than Just Long-Term Investors
Via MarketBeat
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
Via Benzinga
The Latest Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 1, 2023
Via Benzinga
Earnings Preview For Jazz Pharmaceuticals
Via Benzinga
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
Via Benzinga
Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains
Via Benzinga
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
Via Benzinga
Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says
Via Benzinga
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
Via Investor's Business Daily
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
Via Benzinga
2 Cannabis Stocks to Buy for the Long Haul
Via The Motley Fool
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Via Talk Markets
2 Cannabis Stocks That Could Make You Richer
Via The Motley Fool
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
Via Benzinga
3 Cannabis Stocks With Double-Digit Percentage Revenue Growth
Via The Motley Fool
The Ultimate Growth Stocks to Buy With $300 Right Now
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
Via The Motley Fool
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Via Benzinga
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
Via The Motley Fool
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.